Need for a Cardiogenic Shock Team Collaborative-Promoting a Team-Based Model of Care to Improve Outcomes and Identify Best Practices - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38456417/
Cardiogenic shock continues to carry a high mortality rate despite contemporary care, with no breakthrough therapies shown to improve survival over the past few decades. It is a time-sensitive condition...
Cardiogenic shock teams, modeled after the Pulmonary Embolism Response Team Consortium, aim to enhance outcomes through multidisciplinary collaboration, shared protocols, education, and process improvement to address high mortality and resource challenges.
State-of-the-art pulsed field ablation for cardiac arrhythmias: ongoing evolution and future perspective - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38848447/
Pulsed field ablation (PFA) is an innovative approach in the field of cardiac electrophysiology aimed at treating cardiac arrhythmias. Unlike traditional catheter ablation energies, which use radiofrequency or cryothermal energy...
Pulsed field ablation (PFA) uses electroporation for precise cardiac arrhythmia treatment, offering advantages like reduced thermal damage and improved outcomes, revolutionizing catheter ablation with evolving technology and clinical applications.
Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods: A Scientific Statement From the American Heart Association: Endorsed by the Pediatric & Congenital Electrophysiology Society (PACES) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38314551/
Disorders of the cardiac rhythm may occur in both the fetus and neonate. Because of the immature myocardium, the hemodynamic consequences of either bradyarrhythmias or tachyarrhythmias may be far more...
This statement reviews fetal and neonatal arrhythmias, their mechanisms, pharmacological treatments, unique pharmacokinetics, hemodynamic impacts, and highlights research gaps and long-term developmental consequences of interventions and antiarrhythmic medications.
Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39443013/
In IRONMAN, FDI exerted similar reductions in cardiovascular and noncardiovascular hospitalizations, suggesting that correcting iron deficiency might increase resistance or resilience to a broad range of problems that cause hospitalizations...
In the IRONMAN trial, intravenous ferric derisomaltose reduced cardiovascular and noncardiovascular hospitalizations in heart failure patients with iron deficiency, suggesting improved resilience to various health issues. Mortality patterns remained similar between groups.
Artificial intelligence-enhanced electrocardiography for accurate diagnosis and management of cardiovascular diseases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38301492/
Electrocardiography (ECG), improved by artificial intelligence (AI), has become a potential technique for the precise diagnosis and treatment of cardiovascular disorders. The conventional ECG is a frequently used, inexpensive, and...
AI-enhanced ECG improves cardiovascular disease diagnosis by detecting subtle patterns, aiding clinicians, and ensuring timely treatment. Challenges include bias, regulatory barriers, and interpretability, requiring diverse datasets and continuous validation for successful clinical deployment.